CAR T-Cell Therapy Shows Promise for Lupus Patients
A clinical trial at the University of North Carolina explores if cellular reprogramming can improve daily function for those with lupus.
Updated on Oct. 15, 2026 in Arthritis
Live Poll
Should medical research prioritize experimental treatments for chronic diseases with few existing options?
In 2025, a patient named Rachel Dib underwent a clinical trial for CAR T-cell therapy at the University of North Carolina School of Medicine to address lupus. The therapy showed promise in helping the patient manage her daily tasks more than a year after receiving the infusion.
Why it matters
Lupus currently has no cure, and this clinical trial provides a potential new treatment pathway for patients facing this chronic illness. The intervention is being studied as a way to address a condition that affects an estimated 1.5 million Americans, particularly women aged 15 to 44.
This clinical trial of CAR T-cell therapy involves a cohort of lupus patients, with results demonstrating sustained function in individual cases like that of Rachel Dib. The broader efficacy and safety of this approach remain under investigation in ongoing clinical research.
The players
Rachel Dib
A participant in a clinical trial investigating new treatments for lupus.
University of North Carolina School of Medicine
An academic medical institution conducting clinical trials for autoimmune therapies.
The details
To perform this therapy, doctors extract a patient's own T-cells and genetically reprogram them to target and remove autoreactive B cells, which are the immune cells responsible for the damage seen in lupus. Before the infusion, the patient undergoes chemotherapy preconditioning to prepare the immune system for the new, modified cells to engraft and begin their work.
Timeline
• Rachel Dib received her CAR T-cell therapy infusion in 2025.
Health Landscape
The study of CAR T-cell therapy for lupus marks a significant shift in applying cancer-focused cell engineering to treat systemic autoimmune conditions. This approach follows the recent trend of expanding cell therapies beyond oncology to manage chronic, incurable inflammatory diseases.
Lupus remains a complex chronic condition with limited treatment options, making clinical trials an important avenue for patients to monitor. If you are managing lupus, it is worth discussing the current status of emerging immunotherapies with your specialist.
The takeaway
CAR T-cell therapy represents a novel frontier in the treatment of lupus by targeting the immune cells responsible for disease progression. Patients should keep an eye on developments regarding these specialized therapies and consult their physician to see if clinical trial eligibility is relevant.
Further reading
For more information on managing chronic autoimmune conditions, visit the Arthritis section.
Source note: This article includes information reported by WENG 98.1FM, 107.5 FM & 1530 AM.
Live Poll
Should medical research prioritize experimental treatments for chronic diseases with few existing options?
